• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病中的左旋多巴运动并发症

Levodopa motor complications in Parkinson's disease.

作者信息

Obeso J A, Olanow C W, Nutt J G

机构信息

Dept of Neurology and Neurosurgery, Neuroscience Center, Clínica Universitaria and Medical School, Pamplona, Spain.

出版信息

Trends Neurosci. 2000 Oct;23(10 Suppl):S2-7. doi: 10.1016/s1471-1931(00)00031-8.

DOI:10.1016/s1471-1931(00)00031-8
PMID:11052214
Abstract

Parkinson's disease (PD) is an age-related neurodegenerative disorder with an average onset age of 60 years. In the United States, approximately one million persons suffer from PD, and there are 60,000 newly diagnosed cases every year. The estimated cost of PD to society is $27 billion per year. Based on United States Census Bureau projections, it is estimated that the frequency of PD will increase fourfold by the year 2040, making it an even larger burden on patients, their families and society.

摘要

帕金森病(PD)是一种与年龄相关的神经退行性疾病,平均发病年龄为60岁。在美国,约有100万人患有帕金森病,每年有6万例新诊断病例。据估计,帕金森病每年给社会造成的成本为270亿美元。根据美国人口普查局的预测,预计到2040年帕金森病的发病率将增加四倍,这将给患者、其家庭和社会带来更大的负担。

相似文献

1
Levodopa motor complications in Parkinson's disease.帕金森病中的左旋多巴运动并发症
Trends Neurosci. 2000 Oct;23(10 Suppl):S2-7. doi: 10.1016/s1471-1931(00)00031-8.
2
[Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].[帕金森病异动症治疗的药理机制]
Rev Neurol. 1999;28(9):889-98.
3
Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson's disease.多巴胺激动剂、受体选择性与帕金森病中的异动症诱导
Curr Opin Neurol. 2003 Dec;16 Suppl 1:S3-7. doi: 10.1097/00019052-200312001-00002.
4
Continuous dopamine-receptor stimulation in early Parkinson's disease.早期帕金森病中的持续多巴胺受体刺激
Trends Neurosci. 2000 Oct;23(10 Suppl):S117-26. doi: 10.1016/s1471-1931(00)00030-6.
5
Levodopa in the treatment of Parkinson's disease: current controversies.左旋多巴治疗帕金森病:当前争议
Mov Disord. 2004 Sep;19(9):997-1005. doi: 10.1002/mds.20243.
6
Levodopa-dyskinesia incidence by age of Parkinson's disease onset.帕金森病发病年龄对应的左旋多巴诱导的异动症发生率
Mov Disord. 2005 Mar;20(3):342-4. doi: 10.1002/mds.20360.
7
Predictors of motor complications in early Parkinson's disease: A prospective cohort study.早期帕金森病运动并发症的预测因素:一项前瞻性队列研究。
Mov Disord. 2019 Aug;34(8):1174-1183. doi: 10.1002/mds.27783. Epub 2019 Jul 8.
8
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.帕金森病的初始治疗:左旋多巴与多巴胺受体激动剂
J Neurol. 2002 Sep;249 Suppl 2:II25-9. doi: 10.1007/s00415-002-1205-3.
9
New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.帕金森病治疗的新见解:左旋多巴诱导的运动障碍是否可控。
Adv Neurol. 2003;91:51-64.
10
L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach.帕金森病患者左旋多巴诱发的剂峰异动症:一种临床药理学方法
Mov Disord. 1999;14 Suppl 1:19-32.

引用本文的文献

1
Striatal GluN2A gene suppression reduces L-DOPA-induced abnormal involuntary movements in parkinsonian rats.纹状体GluN2A基因抑制可减少帕金森病大鼠中左旋多巴诱导的异常不自主运动。
Neuropharmacology. 2025 Jul 29;279:110616. doi: 10.1016/j.neuropharm.2025.110616.
2
Expert perspectives on the use of safinamide for Parkinson's disease in Portugal: insights from a Portuguese Delphi Consensus.葡萄牙关于沙芬酰胺用于帕金森病治疗的专家观点:葡萄牙德尔菲共识的见解
J Comp Eff Res. 2025 Jul;14(7):e240228. doi: 10.57264/cer-2024-0228. Epub 2025 Jun 6.
3
Identification of a Lipid-Exposed Extrahelical Binding Site for Positive Allosteric Modulators of the Dopamine D Receptor.
鉴定多巴胺D受体正变构调节剂的脂质暴露螺旋外结合位点
ACS Chem Neurosci. 2025 Jun 18;16(12):2295-2311. doi: 10.1021/acschemneuro.5c00105. Epub 2025 May 15.
4
Translational profiling reveals novel gene expression changes in the direct and indirect pathways in a mouse model of levodopa induced dyskinesia.转化分析揭示了左旋多巴诱导的异动症小鼠模型中直接和间接通路中基因表达的新变化。
Front Cell Neurosci. 2025 Mar 12;18:1477511. doi: 10.3389/fncel.2024.1477511. eCollection 2024.
5
Therapeutic innovations for the symptomatic treatment of Parkinson's disease: focus on technology-based therapies.帕金森病症状治疗的治疗创新:聚焦于基于技术的疗法。
J Neural Transm (Vienna). 2025 Mar 22. doi: 10.1007/s00702-025-02915-1.
6
Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson's disease: a disproportionality analysis of the FAERS database.帕金森病中左旋多巴诱发的与苄丝肼和卡比多巴相关的运动并发症:对美国食品药品监督管理局不良事件报告系统(FAERS)数据库的不成比例性分析
Front Pharmacol. 2025 Mar 6;16:1529932. doi: 10.3389/fphar.2025.1529932. eCollection 2025.
7
Selection of DNA aptamers that prevent the fibrillization of α-synuclein protein in cellular and mouse models.在细胞和小鼠模型中筛选可阻止α-突触核蛋白原纤维形成的DNA适配体。
Mol Ther Nucleic Acids. 2024 Jun 15;35(3):102251. doi: 10.1016/j.omtn.2024.102251. eCollection 2024 Sep 10.
8
Exploring the multifaceted role of RASGRP1 in disease: immune, neural, metabolic, and oncogenic perspectives.探讨 RASGRP1 在疾病中的多方面作用:免疫、神经、代谢和致癌角度。
Cell Cycle. 2024 Mar;23(6):722-746. doi: 10.1080/15384101.2024.2366009. Epub 2024 Jun 12.
9
Clinical Management of Movement Disorders.运动障碍的临床管理
J Clin Med. 2023 Dec 21;13(1):43. doi: 10.3390/jcm13010043.
10
The risk of developing motor complications with Levodopa immediate versus dual release upon treatment initiation in Parkinson's disease.帕金森病治疗起始时左旋多巴速释剂与缓释剂引发运动并发症的风险
Clin Park Relat Disord. 2023 Jul 4;9:100209. doi: 10.1016/j.prdoa.2023.100209. eCollection 2023.